We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App





30-Second Coronavirus Test Returns Results as Accurately and Sensitively as PCR Test

By LabMedica International staff writers
Posted on 08 Apr 2022

With any highly infectious disease, time can be a killer. It is crucial to get a test result for a pathogen quickly, lest someone continue in their daily lives infecting others. And delays in testing have undoubtedly exacerbated the COVID-19 pandemic. Unfortunately, the most accurate COVID-19 test often takes 24 hours or longer to return results from a lab. At-home test kits offer results in minutes but are far less accurate or sensitive. Researchers have now developed a COVID-19 testing device that can detect coronavirus infection in as little as 30 seconds as sensitively and accurately as a PCR, or polymerase chain reaction test, the gold standard of testing.

Researchers at the University of Florida (Gainesville, FL, USA) in association with scientists at National Yang Ming Chiao Tung University (Taipei, Taiwan) have developed the device that could transform public health officials’ ability to quickly detect and respond to the coronavirus - or the next pandemic. Like PCR tests, the device is 90% accurate with the same sensitivity, according to a recent peer-reviewed study.

The hand-held apparatus is powered by a 9-volt battery and uses an inexpensive test strip, similar to those used in blood glucose meters, with coronavirus antibodies attached to a gold-plated film at its tip. The strip is placed on the tongue to collect a tiny saliva sample. The strip is then inserted into a reader connected to a circuit board with the brains of the device. If someone is infected, the coronavirus in the saliva binds with the antibodies and begins a dance of sorts as they are prodded by two electrical pulses processed by a special transistor. A higher concentration of coronavirus changes the electrical conductance of the sample. That, in turn, alters the voltage of the electrical pulses.

The voltage signal is amplified a million times and converted to a numerical value - in a sense, the sample’s electrochemical fingerprint. That value will indicate a positive or negative result, and the lower the value, the higher the viral load. The device’s ability to quantify viral and antibody load makes it especially useful for clinical purposes, according to the researchers. The product can be constructed for less than USD 50 in contrast to PCR test equipment which can cost thousands.

Several institutions have worked on devices using a field effect transistor, or FET, like that found in the COVID-19 testing device which the researchers are developing. But those devices are basically one-offs - a sample is applied directly to the FET, which means the transistor is not reusable and must be discarded. That makes those devices expensive and impractical for mass testing. Then the researchers hit upon on the idea of separating the transistor from the sample, like blood glucose meters that use test strips to collect a drop of blood after a lancet pierces a finger. This innovation makes the device unique, affordable and easy to use. The device could be used for venues with large crowds, such as concerts, sporting events, classrooms, in addition to medical settings. The unit would also provide access to accurate, inexpensive testing in rural areas or in developing nations and offers limitless options for personal uses.

The device is not yet approved by the U.S. Food and Drug Administration. First, the researchers will have to ensure that test results are not thrown off by cross-contamination with other pathogens that might be found in the mouth and saliva. These include other coronaviruses, staph infections, the flu, pneumonia and 20 others. The research team is also studying its ability to detect specific proteins that could be used to diagnose other illnesses, including cancer, a heart attack and immune health.

“There is nothing available like it,” said Josephine Esquivel-Upshaw, D.M.D., a professor in the UF College of Dentistry’s department of restorative dental sciences and member of the research team that developed the device. “It’s true point of care. It’s access to care. We think it will revolutionize diagnostics.”

Related Links:
University of Florida
National Yang Ming Chiao Tung University 

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Immunofluorescence Analyzer
MPQuanti
New
Biological Indicator Vials
BI-O.K.
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The experimental blood test accurately indicates severity and predicts potential recovery from spinal cord injury (Photo courtesy of 123RF)

Blood Test Identifies Multiple Biomarkers for Rapid Diagnosis of Spinal Cord Injury

The National Institutes of Health estimates that 18,000 individuals in the United States sustain spinal cord injuries (SCIs) annually, resulting in a staggering financial burden of over USD 9.... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more

Industry

view channel
Image: Tumor-associated macrophages visualized using the Multiomic LS Assay (Photo courtesy of ACD)

Leica Biosystems and Bio-Techne Expand Spatial Multiomic Collaboration

Bio-Techne Corporation (Minneapolis, MN, USA) has expanded the longstanding partnership between its spatial biology brand, Advanced Cell Diagnostics (ACD, Newark, CA, USA), and Leica Biosystems (Nussloch,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.